Skip to main content

Table 1 Patient Characteristics

From: Cerebrospinal fluid metabolic profiling reveals divergent modulation of pentose phosphate pathway by midazolam, propofol and dexmedetomidine in patients with subarachnoid hemorrhage: a cohort study

 

No Sedation

Midazolam

Propofol

Dexmedetomidine

P value

Number of Patients

5

11

13

13

 

Age (years, Mean ± SD)

65.8 ± 7.4

63.3 ± 13.5

61.5 ± 14.2

62.8 ± 11.7

0.94

Gender

 Male

1

6

7

6

0.85

 Female

4

5

6

7

 

Hunt-Hess Scale

 III

4

6

8

9

0.76

 IV

1

5

5

4

 

Fisher Grade

 2

1

1

2

2

0.94

 3 ~ 4

4

10

11

11

 

WFNS SAH grading scale

 II

3

2

4

4

0.42

 III ~ V

2

9

9

9

 

Glasgow Outcome Scale

 Poor (1 ~ 4)

 

8

9

9

0.98

 Good (5)

 

3

4

4

 

RASS Before Sedation

  + 2

2

3

6

7

0.92

  + 3

2

6

5

4

 

  + 4

1

2

2

2

 

RASS After Sedation

  + 1

 

3

5

6

0.81

 0

 

5

4

5

 

 -1

 

3

4

2

 

Other Pharmacological Interventions

 Opioid Analgesics

2

2

4

4

0.76

 Non-Opioid Analgesics

2

2

4

4

0.76

 Mannitol

2

6

9

8

0.55

 Hyperosmotic Saline

2

7

7

7

0.79

 Insulin

3

9

8

10

0.31

 Antihypertensive Agents

3

9

10

11

0.22

 Vasoactive Agents

2

10

10

9

0.15

Comorbidity

 Acute heart failure

2

7

7

7

0.79

 Secondary Hypopituitarism

3

7

6

9

0.35

 Hypertension

1

2

4

3

0.90

 History of stroke or TIA

0

3

4

4

0.49